Producers Online
WithSecure Corporation, Stock Exchange Release, 31 May 2025 at 9:45 EEST WithSecure has completed the transaction of Cyber security consulting divestment to Neqst WithSecure announced on 23 January 2025 its…
Откази на шенгенски визи в Китай: Как се представя България и защо е рекордьор по откази?Данните за 2024 г. отново поставят България в тревожно контрастна позиция спрямо водещите държави в…
WithSecure Corporation, Pörssitiedote, 31.5.2025 klo 9.45 WithSecure on saattanut päätökseen kyberturvakonsultoinnin liiketoiminnan myynnin Neqstille WithSecure tiedotti 23.1.2025 aikeestaan myydä kyberturvakonsultoinnin liiketoiminta ruotsalaiselle sijoitusyhtiö Neqstille. Osapuolet ovat 31.5.2025 saattaneet kaupan päätökseen…
Години наред Шенген беше цел, кауза, мечта и сега ВРЕДИТЕЛСТВОТО целенасочено съсипва туризма . Политици се снимаха с плакати, обещаваха, убеждаваха ни, че „само това ни липсва“, за да дръпнем…
26% preliminary objective response rate observed in heavily pre-treated patients with metastatic microsatellite stable colorectal cancer (MSS CRC) without liver metastases Deep and durable responses ongoing for up to 37…
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a)…
Press release Atos Group receives confirmatory offer from the French State to acquire part of its former Advanced Computing business Vision AI activities excluded from the transaction Confirmatory offer received…
Le groupe Atos reçoit une offre ferme de l'Etat français pour l'acquisition d'une partie de son ancienne activité de Calcul Avancé Les Activités de Vision AI sont exclues de la…
L’essai de Phase III NAPOLI 3 est la plus grande étude interventionnelle réalisée à ce jour avec la plus longue période de suivi des patients avec un adénocarcinome pancréatique métastatique1.L’analyse…
Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with an estrogen receptor 1…